ScreenerHero

MGXMetagenomi Inc. Common Stock

NAS · US · Healthcare · Biotechnology · metagenomi.co
1.230USD-0.81%Mkt Cap: 46.47M $P/E: —

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long prote…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap46.47M $
Enterprise Value-37.61M $
Revenue (TTM)13.56M $
Gross Profit-75.03M $
Net Income (TTM)-87.87M $
Revenue/Share0.3610 USD
Last Price1.230 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.65
PEG—
EV/EBITDA0.39
EV/Revenue-2.77
P/S3.34
P/B0.40
EPS (TTM)-2.39
EPS (Forward)-1.83
52W Range
1.1304% of range3.950
52W High3.950 USD
52W Low1.130 USD
Profitability
Gross Margin0.00%
Oper. Margin11195.72%
EBITDA Margin0.00%
Profit Margin-348.54%
ROE-55.40%
ROA-39.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.89M $
CapEx (TTM)574.00K $
FCF Margin-375.72%
FCF Yield-109.65%
Net Debt-82.94M $
Net Debt/EBITDA0.87
Balance Sheet
Debt/Equity0.26
Current Ratio4.50
Quick Ratio4.40
Book Value/Sh2.980 USD
Cash/Share3.194 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+469.1%
Target Range5.000 USD – 9.000 USD
$5.000+469.1% to mean$9.000
# Analysts3
Ownership
Shares Out.37.78M
Float25.57M
Insiders18.90%
Institutions18.72%
Short Interest
Short Ratio7.8d
Short % Float4.87%
Short % Out.3.95%
Shares Short1.49M
Short (prev mo.)1.68M
Technical
SMA 501.227 (+0.3%)
SMA 2001.477 (-16.7%)
Beta0.67
S&P 52W Chg18.16%
Avg Vol (30d)168.33K
Avg Vol (10d)141.04K
Technical Indicators
RSI (14)50.0
MACD-0.0030
MACD Signal-0.0062
MACD Hist.+0.0032
BB Upper1.244 USD
BB Middle1.219 USD
BB Lower1.194 USD
BB Width4.14%
ATR (14)0.0431 USD
Vol Ratio (20d)2.14x